What's in Les Laboratoires des Médicaments Stériles's pipeline?

Les Laboratoires des Médicaments Stériles has 8 drugs in our index: 8 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Les Laboratoires des Médicaments Stériles's portfolio?

Top competitors by shared drug class: Athens Medical Center, Gan & Lee Pharmaceuticals., Institut de Recherches Cliniques de Montreal, Jiangsu HengRui Medicine Co., Ltd., Merete Bechmann Christensen.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/les-laboratoires-des-m-dicaments-st-riles.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Les Laboratoires des Médicaments Stériles — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Les Laboratoires des Médicaments Stériles pipeline: 8 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Pidogrel	Pidogrel	marketed			Other
Dosage of PT-INR	Dosage of PT-INR	marketed
optimized quadruple therapy	optimized quadruple therapy	marketed
ENOXA®	ENOXA®	marketed		RISC-loading complex subunit TARBP2, V-type proton ATPase subunit B, brain isoform, DNA gyrase	Infectious Disease
switch NPH to glargin	switch NPH to glargin	marketed	Long-acting basal insulin analog	Insulin receptor	Diabetes
Enoxaparin 4000 IU	Enoxaparin 4000 IU	marketed
Anti Xa dosage	Anti Xa dosage	marketed
standard quadruple therapy	standard quadruple therapy	marketed	Antimicrobial combination therapy		Infectious Disease

Therapeutic area mix

Infectious Disease · 2
Diabetes · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Athens Medical Center · 1 shared drug class
Gan & Lee Pharmaceuticals. · 1 shared drug class
Institut de Recherches Cliniques de Montreal · 1 shared drug class
Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class
Merete Bechmann Christensen · 1 shared drug class
Nanjing First Hospital, Nanjing Medical University · 1 shared drug class
Novo Nordisk A/S · 1 shared drug class
Sydney Children's Hospitals Network · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Les Laboratoires des Médicaments Stériles:

Cite this brief

Drug Landscape (2026). Les Laboratoires des Médicaments Stériles — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/les-laboratoires-des-m-dicaments-st-riles. Accessed 2026-05-17.